Lenalidomide and Obinutuzumab in Treating Patients With Relapsed Indolent Non-Hodgkin Lymphoma
Status:
Active, not recruiting
Trial end date:
2022-05-31
Target enrollment:
Participant gender:
Summary
This phase I/II trial studies the side effects and best dose of lenalidomide when given
together with obinutuzumab and how well this combination works in treating patients with
low-grade non-Hodgkin lymphoma (NHL) that has returned after a period of improvement
(relapsed). Biological therapies, such as lenalidomide, may attack specific cancer cells and
stop them from growing or kill them. Obinutuzumab is a form of targeted therapy because it
attaches itself to specific molecules (receptors) on the surface of cancer cells, known as
CD20 receptors. When obinutuzumab attaches to CD20 receptors, the signals that tell the cells
to grow are blocked and the cancer cell may be marked for destruction by the body's immune
system. Giving lenalidomide and obinutuzumab together may work better in treating NHL.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborators:
Celgene Genentech, Inc. National Cancer Institute (NCI)